Grassley Mows Down FDA Handling Of ADHD Drug Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
Adverse events need a “comprehensive review,” Senate Finance Committee Chairman says, questioning FDA’s approach to advisory committees.